<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
"http://www.w3.org/TR/REC-html40/loose.dtd"> 
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
</head>
<body>
<p>

# en/ELRC-vaccination.xml.gz<br>
# mt/ELRC-vaccination.xml.gz

<p><hr>
(src)="240"> its purity ; <br>
(trg)="1"> il - purità tiegħu ; <br>
<hr>
(src)="249"> Are there serious side effects ? <br>
(trg)="2"> Hemm effetti sekondarji serji ? <br>
<hr>
(src)="235"> its ingredients , including its inactive ingredients or ‘ excipients ' ; <br>
(trg)="4"> l - ingredjenti tiegħu , inkluż l - ingredjenti mhux attivi tiegħu jew l - " eċċipjenti " ; <br>
<hr>
(src)="248"> Does the vaccine seem to work ? <br>
(trg)="5"> Il - vaċċin huwa sikur ? <br>
<hr>
(src)="254"> This involves tests in the laboratory and in animals . <br>
(trg)="7"> Dan jinvolvi testijiet fil - laboratorju u fl - annimali . <br>
<hr>
(src)="243"> At the end of the testing programme , the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘ marketing authorisation ' application . <br>
(trg)="9"> Fl - aħħar tal - programm ta ' ttestjar , l - iżviluppatur tal - vaċċin jissottometti r - riżultati lill - awtoritajiet regolatorji tal - mediċini fl - Ewropa bħala parti minn applikazzjoni ta ' " awtorizzazzjoni għat - tqegħid fis - suq " . <br>
<hr>
(src)="250"> This is followed by a clinical testing programme in humans , which can take around ten years from initial concept to authorisation and must adhere to strict standards . <br>
(trg)="10"> Dan jiġi segwit minn programm ta ' ttestjar kliniku fil - bnedmin , li jista ' jieħu sa għaxar snin mill - kunċett inizjali sal - awtorizzazzjoni u għandu jaderixxi ma ' standards stretti . <br>
<hr>
(src)="253"> What are the most common side effects ? <br>
(trg)="11"> Liema huma l - effetti sekondarji l - aktar komuni ? <br>
<hr>
(src)="252"> The companies are required to conduct stringent testing , for which the acceptance criteria are pre-defined by the authorities , on each batch of vaccine released onto the EU market . <br>
(trg)="13"> Il - kumpaniji huma meħtieġa jwettqu ttestjar strinġenti , li għalih , il - kriterji tal - aċċettazzjoni tiegħu jiġu definiti minn qabel mill - awtoritajiet , fuq kull lott ta ' vaċċini rilaxxat fis - suq tal - UE . <br>
<hr>
(src)="251"> how it is manufactured . <br>
(trg)="15"> kif jiġi manifatturat . <br>
<hr>
(src)="113"> Twitter Facebook Linked In Mail <br>
(trg)="17"> Benefiċċji tat - tlaqqim <br>
<hr>
(src)="241"> Testing includes checking the vaccine 's quality : <br>
(trg)="18"> L - ittestjar jinkludi li tiġi ċċekkjata l - kwalità tal - vaċċin : <br>
<hr>
(src)="242"> The vaccine developer tests the vaccine in three phases of clinical trials , with larger numbers of people in each phase . <br>
(trg)="19"> L - iżviluppatur tal - vaċċin jittestja l - vaċċin fi tliet fażijiet ta ' provi kliniċi , b'numri akbar ta ' persuni f'kull fażi . <br>
<hr>
(src)="245"> The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine 's benefits are greater than its risks . <br>
(trg)="20"> Ir - regolaturi jistgħu japprovaw il - vaċċin biss jekk l - evalwazzjoni xjentifika tar - riżultati tat - testijiet tiegħu turi li l - benefiċċji tal - vaċċin huma akbar mir - riskji tiegħu . <br>
<hr>
(src)="495"> Then the vaccine developer tests the vaccine 's effects . <br>
(trg)="22"> Imbagħad l - iżviluppatur tal - vaċċin jittestja l - effetti tal - vaċċin . <br>
<hr>
(src)="247"> They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly . <br>
(trg)="24"> Dawn jistgħu wkoll jagħmlu testijiet biex jiżguraw li l - lottijiet tal - vaċċini rilaxxati fis - suq ikunu tal - kwalità mistennija u jkunu ġew manifatturati kif suppost . <br>
<hr>
(src)="328"> Vaccination is the only way to ensure direct protection against tetanus . <br>
(trg)="26"> It - tilqim huwa l - uniku mod li jiżgura protezzjoni diretta kontra t - tetnu . <br>
<hr>
(src)="330"> For example , to ensure community immunity against measles , public health authorities recommend that 95 % of the population are vaccinated with two doses of the vaccine against measles ( the MMR vaccine , which protects against measles , mumps and rubella ) . <br>
(trg)="27"> Pereżempju , biex jiżguraw l - immunità komunitarja kontra l - ħosba , l - awtoritajiet tas - saħħa pubblika jirrakkomandaw li 95 % tal - popolazzjoni jitlaqqmu b'żewġ dożi tal - vaċċin kontra l - ħosba ( il - vaċċin MMR , li jipproteġi kontra l - ħosba , il - gattone u r - rubella ) . <br>
<hr>
(src)="331"> Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases , reducing the risk of diseases spreading among family members , school mates or colleagues , friends , neighbours and other people in the community . <br>
(trg)="28"> It - tilqim jipproteġi lill - persuni mlaqqma u lill - persuni ta ' madwarhom li huma vulnerabbli għall - mard , inaqqas ir - riskju li l - mard jinfirex fost il - membri tal - familja , ħbieb tal - iskola , kollegi , ħbieb , ġirien u persuni oħrajn fil - komunità . <br>
<hr>
(src)="332"> Furthermore , immunisation programmes help reduce the social , psychological and financial burdens of disease on people and governments , reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment . <br>
(trg)="30"> Barra minn hekk , il - programmi tal - immunizzazzjoni jgħinu biex inaqqsu l - piżijiet soċjali , psikoloġiċi u finanzjarji tal - mard fuq in - nies u l - gvernijiet , inaqqsu l - pressjonijiet fuq is - sistemi tal - kura tas - saħħa u tal - kura soċjali u jippermettu lin - nies iwettqu attivitajiet produttivi li jinkludu l - edukazzjoni u l - impjieg . <br>
<hr>
(src)="336"> Community immunity occurs when enough people in a population are immune to an infectious disease <br>
(trg)="31"> L - immunità komunitarja sseħħ meta biżżejjed persuni f'popolazzjoni jkunu immuni għal marda infettiva . <br>
<hr>
(src)="329"> For example , tetanus can be encountered due to common injuries , including dog or cat bites . <br>
(trg)="33"> Pereżempju , it - tetnu jista ' jittieħed minħabba korrimenti komuni , inkluż gdim tal - klieb jew tal - qtates . <br>
<hr>
(src)="129"> Benefits of vaccination for individuals <br>
(trg)="35"> Benefiċċji tat - tilqim għall - individwi <br>
<hr>
(src)="337"> These include babies , children , the elderly , people with weak immune systems , cancer patients , and people who cannot be vaccinated for medical reasons . <br>
(trg)="36"> Dawn jinkludu t - trabi , it - tfal , l - anzjani , il - persuni b'sistemi immunitarja dgħajfa , pazjenti bil - kanċer , u persuni li ma jistgħux jitlaqqmu minħabba raġunijiet mediċi . <br>
<hr>
(src)="484"> In this way , vaccines indirectly protect others who are vulnerable to disease . <br>
(trg)="37"> B'dan il - mod , il - vaċċini b'mod indirett jipproteġu lill - persuni l - oħra li jkunu vulnerabbli għall - marda . <br>
<hr>
(src)="146"> Up to 50 % of people infected with rubella do not experience symptoms . <br>
(trg)="39"> Sa 50 % tal - persuni infettati bir - rubella ma jesperjenzawx sintomi . <br>
<hr>
(src)="153"> The MMR ( measles , mumps and rubella ) vaccine is a combination vaccine that protects against measles , mumps and rubella . <br>
(trg)="40"> Il - vaċċin MMR ( il - ħosba , il - gattone u r - rubella ) huwa vaċċin ikkombinat li jipproteġi kontra l - ħosba , il - gattone u r - rubella . <br>
<hr>
(src)="166"> Rubella ( German measles ) is a viral infection . <br>
(trg)="41"> Ir - Rubella ( il - ħosba Ġermaniża ) hija infezzjoni virali . <br>
<hr>
(src)="155"> What are the symptoms of rubella ? <br>
(trg)="43"> X'inhuma s - sintomi tar - rubella ? <br>
<hr>
(src)="161"> The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes . <br>
(trg)="45"> Il - virus tar - rubella jinfirex minn taqtiriet fl - arja li jiġu prodotti meta l - persuna infettata tisgħol u tagħtas . <br>
<hr>
(src)="25"> The MMR vaccine is safe and effective and has very few side effects . <br>
(trg)="47"> Il - vaċċin MMR huwa sikur u effikaċi u ma tantx għandu effetti sekondarji . <br>
<hr>
(src)="164"> The consequences for unvaccinated pregnant women that get rubella are particularly severe , due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies . <br>
(trg)="48"> Il - konsegwenzi għan - nisa tqal li mhumiex imlaqqma li taqbadhom ir - rubella huma partikolarment severi , probabbli minħabba l - fatt li l - marda waqt it - tqala tista ' twassal għal korriment jew CRS fit - trabi tagħhom . <br>
<hr>
(src)="149"> Some vaccine recipients develop a non-infectious mild measles-like rash , typically 7-14 days after vaccination , which disappears within 1-3 days . <br>
(trg)="50"> Xi reċipjenti tal - vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill - ħosba , tipikament bejn sebat ijiem u 14 - il jum wara t - tilqima , li jisparixxi bejn jum u tlett ijiem wara . <br>
<hr>
(src)="156"> However , if a woman gets rubella during the first three months of pregnancy , it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome ( CRS ) . <br>
(trg)="51"> Madankollu , jekk mara taqbadha r - rubella matul l - ewwel tliet xhur tat - tqala , x'aktarx li tirriżulta f'korriment jew f'tarbija li titwieled b'disturbi konġenitali magħrufa bħala sindrome tar - rubella konġenitali ( CRS ) . <br>
<hr>
(src)="151"> Women who plan to become pregnant should check their vaccination status , as they cannot be vaccinated against rubella during pregnancy . <br>
(trg)="53"> In - nisa li beħsiebhom joħorġu tqal għandhom jivverifikaw l - istatus ta ' tilqim tagħhom , peress li ma jistgħux jitlaqqmu kontra r - rubella matul it - tqala . <br>
<hr>
(src)="162"> Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella . <br>
(trg)="55"> Kull min għadha ma qabditux il - marda jew min ma kienx imlaqqam bil - vaċċin MMR qiegħed f'riskju li taqbdu r - rubella . <br>
<hr>
(src)="159"> CRS can lead to deafness , cataracts and learning disabilities in the baby . <br>
(trg)="57"> Is - CRS tista ' twassal għal truxija , katarretti u diżabilitajiet fit - tagħlim fit - tarbija . <br>
<hr>
(src)="4"> Two doses of the vaccine are needed for maximum protection . <br>
(trg)="59"> Għall - protezzjoni massima huma meħtieġa żewġ dożi tal - vaċċin . <br>
<hr>
(src)="163"> How is rubella treated ? <br>
(trg)="60"> Kif tista ' tiġi pprevenuta r - rubella ? <br>
<hr>
(src)="130"> In Europe , influenza occurs ... <br>
(trg)="62"> Fl - Ewropa , l - influwenza sseħħ . . . <br>
<hr>
(src)="123"> Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood ... <br>
(trg)="64"> Kull virus u batterju joħloq reazzjoni unika fis - sistema immunitarja li tinvolvi sett speċifiku ta ' ċelloli fid - demm . . . <br>
<hr>
(src)="125"> Vaccination protects individuals against diseases that could have serious consequences for ... <br>
(trg)="65"> It - tilqim jipproteġi lill - individwi kontra mard li jista ' jkollu konsegwenzi serji għal . . . <br>
<hr>
(src)="131"> Human papillomavirus ( HPV ) infection is a viral infection that is mainly sexually transmitted by direct contact ... <br>
(trg)="66"> Ir - rubella ( il - ħosba Ġermaniża ) hija infezzjoni virali . <br>
<hr>
(src)="121"> When to vaccinate <br>
(trg)="68"> Tagħbija aktar <br>
<hr>
(src)="128"> Vaccines are recommended for different age ... <br>
(trg)="70"> Il - vaċċini huma rakkomandati għal gruppi ta ' etajiet differenti . . . <br>
<hr>
(src)="114"> Trusted sources <br>
(trg)="72"> Aqra iktar <br>
<hr>
(src)="117"> It also provides an overview of the mechanisms in place in the European Union ( EU ) to ensure that available vaccines conform to the highest standards of safety and effectiveness . <br>
(trg)="73"> Dan jipprovdi wkoll ħarsa ġenerali lejn il - mekkaniżmi implimentati fl - Unjoni Ewropea ( UE ) biex jiġi żgurat li l - vaċċini jikkonformaw mal - ogħla standards ta ' sigurtà u effettività . <br>
<hr>
(src)="122"> The main purpose of this website is to provide accurate , objective , up-to-date evidence on vaccines and vaccination . <br>
(trg)="75"> L - iskop ewlieni ta ' dan is - sit web huwa li jipprovdi evidenza preċiża , oġġettiva u aġġornata dwar il - vaċċini u t - tilqim . <br>
<hr>
(src)="72"> Safety , quality and standards <br>
(trg)="77"> Sikurezza , kwalità ustandards <br>
<hr>
(src)="77"> Serious side effects are very rare . <br>
(trg)="78"> Effetti sekondarji serji huma rari ħafna . <br>
<hr>
(src)="91"> Recently , a vaccine was developed against Ebola virus disease , and research is underway on vaccines to protect against human immunodeficiency virus ( HIV ) . <br>
(trg)="80"> Dan l - aħħar , ġiet żviluppata tilqima kontra l - virus tal - marda tal - Ebola , u qed issir riċerka dwar tilqim li jipproteġu kontra l - virus tal - immunodefiċjenza umana ( HIV ) . <br>
<hr>
(src)="113"> Twitter Facebook Linked In Mail <br>
(trg)="81"> Fatti dwar it - tilqim <br>
<hr>
(src)="82"> Vaccines work by ‘ teaching ' a person 's immune system ( the body 's natural defences ) to defend itself against a specific disease . <br>
(trg)="83"> It - tilqim jaħdem billi ‘ jgħallem ' lis - sistema immunitarja ( id - difiżi naturali tal - ġisem ) biex tiddefendi ruħha kontra marda speċifika . <br>
<hr>
(src)="74"> The first vaccine was developed in the 18th century in the United Kingdom . <br>
(trg)="85"> L - ewwel tilqima ġiet żviluppata fis - seklu 18 fir - Renju Unit . <br>
<hr>
(src)="85"> This evaluation needs to show that a vaccine 's benefits in protecting people against diseases are far greater than any potential risk . <br>
(trg)="86"> Din l - evalwazzjoni teħtieġ turi li l - benefiċċji tat - tilqima fil - protezzjoni tan - nies kontra l - mard humaħafna akbar minn kwalunkwe riskju potenzjali . <br>
<hr>
(src)="90"> As with any medicine , some people may experience side effects from a vaccine , but these are usually mild and short-lived . <br>
(trg)="88"> Bħal kull mediċina oħra , xi wħud min - nies jistgħu jesperjenzaw effetti sekondarji mit - tilqima , iżda dawn ikunu ġeneralment ħfief u ma jdumux . <br>
<hr>
(src)="89"> Smallpox is now eradicated worldwide in humans thanks to vaccination . <br>
(trg)="90"> Qabel kwalunkwe tilqima ġdida tkun tista ' tintuża , irid isirilha ttestjar rigoruż . <br>
<hr>
(src)="83"> They can include mild fever , or pain or redness at the injection site . <br>
(trg)="92"> Il - ġidri , illum il - ġurnatanqerdet mid - dinja kollha fil - bnedmin bis - saħħa tat - tilqim . <br>
<hr>
(src)="279"> vaccinating against humanpapilloma virus ( HPV ) can help prevent cervical and other cancers caused by HPV infection ; <br>
(trg)="94"> it - tilqim kontra l - virus tal - papilloma umana ( HPV ) jista ' jgħin biex jipprevjeni kanċer ċervikali u kanċers oħrajn ikkawżati mill - infezzjoni tal - HPV ; <br>
<hr>
(src)="263"> 1-4 people <br>
(trg)="96"> L - Influwenza <br>
<hr>
(src)="480"> Source : Plotkin S , Orenstein W , Offit P. Vaccines . <br>
(trg)="97"> Il - programmi tat - tilqim għandhom benefiċċji usa ' għas - soċjetà . <br>
<hr>
</body>
</html>
